¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma thromboplastic factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma coagulase
    Ç÷ÀåÀÀ°íÈ¿¼Ò
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma cross matching
    Ç÷Àå±³Â÷½ÃÇè
  • plasma exchange
    Ç÷À屳ȯ(¼ú)
  • plasma expander
    Ç÷ÀåÁõ·®Á¦
  • plasma hemoglobin
    Ç÷ÀåÇ÷»ö¼Ò
  • plasma iron
    Ç÷Àåö
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
  • plasma membrane
    ÇüÁú¸·
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma substitute
    Ç÷Àå´ëüÁ¦
  • plasma volume expander
    Ç÷ÀåÁõ·®Á¦
  • pooled blood plasma
    È¥ÇÕÇ÷Àå
  • seminal plasma
    Á¤¾×Àå¾×
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷À¯¹æ¿°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾
  • plasma cross matching
    (¢¡cross matching) Ç÷Àå±³Â÷½ÃÇè
  • plasma
    Ç÷Àå, ¿øÇüÁú, ¼¼Æ÷Áú
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma substitute
    Ç÷Àå´ëÄ¡Á¦
  • plasma component transfusion
    Ç÷À强ºÐ¼öÇ÷
  • plasma iron pool
    Ç÷ÀåöÀúÀå°í
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À²
  • pooled blood plasma
    È¥ÁÖÇ÷Àå
  • seminal plasma
    Á¤¾×Àå¾×
  • true plasma
    ¼øÇ÷Àå
  • stable plasma protein solution
    ¾ÈÁ¤Ç÷Àå´Ü¹é¿ë¾×
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • plasma cell
    ÇüÁú(û¡òõ)¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà).
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷ÀÌȥȭÁõ
  • plasma cell dyscrasia
    ÇüÁú¼¼Æ÷Áúȯ(û¡òõá¬øàòðü´), ÇüÁú¼¼Æ÷Àå¾Ö(¡­î¡äô), ÇüÁú¼¼Æ÷ÀÌȥȭÁõ(¡­ì¶ûèûúñø)
  • plasma cell gingivostomatitis
    ÇüÁú¼¼Æ÷ Ä¡Àº ±¸³»¿°
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷¼º ¹éÇ÷º´(û¡òõá¬øààõ ÛÜúìÜ»)
  • plasma cell leukemia
    ÇüÁú¼¼Æ÷ ¹éÇ÷º´
  • plasma cell mastitis
    ÇüÁú¼¼Æ÷¼ºÀ¯¹æ¿°(û¡òõá¬øààõêáÛ®æú)
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷ °ñ¼öÁ¾
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾(û¡òõá¬øàÍéâÐðþ)
  • plasma cell pneumonia
    ÇüÁú¼¼Æ÷¼º Æó·Å.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • effective renal plasma flow =ERPF
    À¯È¿½ÅÇ÷Àå·ù·®(êóüùãìúìíì×µÕá).
  • effective renal plasma flow =ERPF
    À¯È¿½ÅÇ÷Àå·ù·®.
  • fresh frozen plasma
    ½Å¼±³Ãµ¿Ç÷Àå.
  • fresh frozen plasma=FFP
    ½Å¼±µ¿°áÇ÷Àå
  • frozen plasma
    ³Ãµ¿Ç÷Àå
  • inflammation,plasma proteases
    Ç÷Àå ÇÁ·ÎÅ×¾ÆÁ¦(úìíì ¡­)
  • interstitial plasma cell pneumonia
    °£Áú¼º ÇüÁú¼¼Æ÷Æó·Å.
  • liquid plasma
    ¾×»óÇ÷Àå(äûßÒúìíì).
  • lymph plasma
    ¸²ÇÁÀå¾×
  • oxalated plasma
    ¿Á»ì»ê÷°¡Ç÷Àå(?Ì´Ëö).
  • plasma
    Ç÷Àå
  • plasma
    Ç÷Àå(úìíì), ÇöóÁ.
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • plasma cell
    ÇüÁú¼¼Æ÷
  • plasma cell
    ÇüÁú(û¡òõ)¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasma transglutaminase
    Ç÷Àå(úìíì) Æ®¶õ½º±Û·çŸ¹Ì³×À̽º
  • separated plasma
    ºÐ¸®Ç÷Àå(ÝÂ×îúìíì)
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • true plasma
    ¼øÇ÷Àå(âíúìíì)
  • whole plasma
    ÀüÇ÷Àå(îïúìíì)
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
  • antianemia factor
    Ç׺óÇ÷ÀÎÀÚ(ù÷Þ¸úìì×í­)
  • antiberiberi factor
    Ç×°¢±âÀÎÀÚ(ù÷ÊÅѨì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
TAAF thromboplastic activity of the amniotic fluid
TCC terminal complement complex; thromboplastic cell component; transitional-cell carcinoma; trichloroca...
FENa, FeNa Fractional Excretion of Sodium
  ; VolumeÀÇ °³³äÀ» Á¦°ÅÇÏ¿© Á» ´õ Á¤È®ÇÑ ½ÅÀåÀÇ ³óÃà ´É·ÂÀ» Æò°¡,
 &n...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
D/P Dialysate/plasma
ERPF Effective Renal Plasma Flow
FPG Fasting plasma glucose
FPI Fasting plasma insulin
FFP Fresh Frozen Plasma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plasma protein
    Ç÷Àå ´Ü¹é, Ç÷Àå ´Ü¹éÁú
    1. Ç÷Àå¿¡ Á¸ÀçÇÏ´Â ¿©·¯ Á¾·ùÀÇ ´Ü¹éÁú. ¿î¹Ý ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma substitute
    Ç÷Àå ´ë¿ëÁ¦
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pooled plasma
    È¥ÁÖ Ç÷Àå
  • renal plasma flow
    ½Å Ç÷Àå·ù, ½Å Ç÷Àå·ù·®
  • venous plasma blood glucose
    Á¤¸Æ Ç÷Àå Ç÷´çÄ¡, Á¤¸Æ Ç÷Àå Ç÷´ç
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • accessory food factor
    ¿µ¾ç º¸Á¶ ÀÎÀÚ
    F.G Ho
  • air kerma calibration factor
    °ø±â Ä¿¸¶ ÃøÁ¤ °è¼ö, ´«±Ý ¸ÂÃã °è¼ö
  • alveolar dilution factor
    ÆóÆ÷ Èñ¼® ÀÎÀÚ
  • angiogenesis factor
    Ç÷°ü Çü¼º ÀÎÀÚ
    ½Å»ý Ç÷°ü Áõ½ÄÀ» À¯µµÇÏ´Â ¹°Áú·Î¼­, Á¾¾çÀ̳ª ¸Á¸· °°Àº ½ÅÁø´ë»ç·®ÀÌ Å« Á¶Á÷¿¡¼­ ¹ß°ßµÈ´Ù. ÀÌ ÀÎÀÚ´Â »óóÀÇ °¡ÀåÀÚ¸®³ª Ç¥¸é¿¡ ÀÖ´Â Àú»ê¼Ò »óÅÂÀÇ ´ë½Ä¼¼Æ÷¿¡¼­ ºÐºñµÇ¸ç, »óó Ä¡À¯ °úÁ¤¿¡¼­ Ç÷°ü ÀçÇü¼ºÀ» À¯µµÇÑ´Ù.
  • anisotropy factor
    ºñµî¹æ¼º °è¼ö
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
granuloma, plasma cell A slow-growing benign pseudotumour in which plasma cells greatly outnumber the inflammatory cells.
(12 Dec 1998)
granuloma, plasma cell, orbital A distinctive, chronic inflammatory reaction in the orbital tissues of the eye, of unknown aetiology, that may closely resemble a neoplasm and often becomes bilateral. Symptoms include exophthalmos and congestion of the lids with oedema. When limitation of ocular motility also occurs, it is sometimes called orbital myositis.
(12 Dec 1998)
granuloma, plasma cell, pulmonary A pseudotumour of the lung composed of inflammatory cells and showing complete maturity of fibroblastic components with a striking lack of mitosis. It is also called postinflammatory pseudotumour and pseudoneoplastic pneumonitis. (berardi, r.s. Et al. Inflammatory pseudotumours of the lung. Surg gynecol obstet 156:89-96, jan 83)
(12 Dec 1998)
collisionless plasma model <radiobiology> Model of a plasma in which the density is so low, or the temperature so high, that close binary (two-body) collisions have practically no significance (on certain timescales) because the time scales of interest are shorter than the collision time. Yields valid physical results for timescales much shorter than the average collision time in a real plasma.
(09 Oct 1997)
plasma <haematology> Acellular fluid in which blood cells are suspended. Serum obtained by defibrinating plasma (plasma derived serum) lacks platelet released factors and is less suitable to support the growth of cells in culture.
(13 Oct 1997)
plasma accelerator globulin <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
plasma albumin <protein> The serum level of the low molecular protein albumin. Albumin, produced by the liver, plays an important role in maintaining plasma oncotic pressure. Normal serum albumin should be 3.5-5.0 grams per decilitre. Low serum albumin can be found in cases of liver disease and malnutrition.
(27 Sep 1997)
plasma cell <haematology> A terminally differentiated antibody forming and usually antibody secreting, cell of the B-cell lineage.
(18 Nov 1997)
plasma cell balanitis Benign circumscribed balanitis characterised microscopically by subepithelial plasma cell infiltration and clinically by small erythematous papular lesions.
Synonym: balanitis circumscripta plasmacellularis, balanitis of Zoon, Zoon's erythroplasia.
(05 Mar 2000)
plasma cell dyscrasia A diverse group of diseases characterised by the proliferation of a single clone of cells producing a monoclonal immunoglobulin or immunoglobulin fragment (a serum M component). The cells usually have plasma cell morphology, but may have lymphocytic or lymphoplasmacytic morphology. This group includes multiple myeloma, Waldenstrom's macroglobulinaemia, the heavy chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis.
(05 Mar 2000)
plasma cell gingivitis Intense hyperaemic oedema and inflammation of the gingiva resulting from a hypersensitivity reaction. A dense plasma cell infiltrate is seen in the lamina propria.
Synonym: atypical gingivitis.
(05 Mar 2000)
plasma cell hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
plasma cell leukaemia An unusual disease characterised by leukocytosis and other signs and symptoms that are suggestive of leukaemia, in association with diffuse infiltrations and aggregates of plasma cells in the spleen, liver, bone marrow, and lymph nodes, and the presence of considerable numbers of plasma cells in the circulating blood; the total number of leukocytes in the latter may range from normal levels to 80,000 or 90,000 per cu mm, and 5 to 90% may be plasma cells; multiple myelomas are observed in some examples of plasma cell leukaemia, but discrete nodules are not formed in bone. Although there are other clinicopathologic differences in the two conditions, they may be phases of the same basic process.
(05 Mar 2000)
plasma cell mastitis A condition of the breasts characterised by tumourlike indurated masses containing numerous plasma cells, usually resulting from mammary duct ectasia; although clinically resembling malignant disease (attachment to skin and enlargement of axillary lymph nodes), it is not neoplastic.
(05 Mar 2000)
plasma cell myeloma Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á